Company Overview
Snapshot
Founded in December 2011 by Ohad Schwartz and Prof. Itzhak Binderman, CoreBone operates with 1–10 employees. The company has raised $6.32M across three funding rounds from five investors. In October 2021, CoreBone secured a $3.7 million investment to commercialize its bioactive bone graft material and expand its activities in China.
Business overview
CoreBone develops and commercializes bioactive coral-based bone grafts for dental and orthopedic applications. The company's biomimetic bone graft material is cultured in a controlled system, allowing for enrichment with silicium and strontium to enhance bioactivity and strength. CoreBone's products, including CoreBon1000, CoreBlock, CoreBlock Cone, CoreBone 500, and CoreBone 2000, are CE and ISO 13485 certified, serving the health tech and life sciences sectors, particularly in biomaterials and tissue engineering, with a focus on B2B distribution channels in markets such as China and Europe.
Strategic signal
In October 2021, CoreBone raised a $3.7 million investment, led by Guangzhou Sino-Israel Biotech Investment Fund (GIBF), specifically earmarked for the commercialization of its bioactive bone graft material and expansion into the Chinese market. This funding signals strong investor confidence in the company's product readiness and its strategic intent to capture significant market share in key international regions, indicating a pivotal phase of growth and market penetration.
Log in to access full profile ›Company Intelligence Q&A
- What is CoreBone's primary product?
- CoreBone's primary product is a bioactive coral-based bone graft material designed for dental and orthopedic treatments. It offers bone-like qualities such as strength, porosity, resorption, and bioactivity without being derived from human or animal bone.
- When was CoreBone founded and by whom?
- CoreBone was founded in December 2011 by Ohad Schwartz and Prof. Itzhak Binderman.
- What significant investment did CoreBone receive in October 2021?
- In October 2021, CoreBone raised a $3.7 million investment, led by Guangzhou Sino-Israel Biotech Investment Fund (GIBF), to commercialize its bioactive bone graft material and expand its activity in China.
- What certifications do CoreBone's products hold?
- CoreBone's products are CE and ISO 13485 certified, indicating compliance with European health, safety, and environmental protection standards and international quality management systems for medical devices.
- Which investor participated in CoreBone's Seed round in January 2013?
- In January 2013, The Trendlines Group participated in CoreBone's Seed funding round.